P70S6 kinase is a critical node that integrates HER-family and PI3 kinase signaling networks

Cellular Signalling

Volumn 26, Issue 8, 2014, Pages 1627-1635

  Axelrod, Mark J ^a   Gordon, Vicki ^a   Mendez, Rolando E ^a   Leimgruber, Stephanie S ^a   Conaway, Mark R ^a   Sharlow, Elizabeth R ^a   Jameson, Mark J ^a   Gioeli, Daniel G ^a   Weber, Michael J ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Adaptive response; Fragile node; HER family; MAP kinase; P70S6 kinase; PI3 kinase; Signaling networks

Indexed keywords

2 [1 (3 AMIDINOTHIOPROPYL) 1H INDOL 3 YL] 3 (1 METHYL 1H INDOL 3 YL)MALEIMIDE; 4 [1 (3 FLUOROBENZYL) 5 INDAZOLYLAMINO] 5 METHYLPYRROLO[2,1 F][1,2,4]TRIAZINE 6 CARBAMIC ACID 3 MORPHOLINOMETHYL ESTER; AT 7867; DACTOLISIB; ENZYME INHIBITOR; HER FAMILY KINASE INHIBITOR; HER PROTEIN; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; P70S6 KINASE; PF 04691502; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHOTRANSFERASE; PROTEIN S6; UNCLASSIFIED DRUG; EPIDERMAL GROWTH FACTOR RECEPTOR; IMIDAZOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; QUINOLINE DERIVATIVE; S6 KINASE; TARGET OF RAPAMYCIN KINASE;

ADAPTATION; ADAPTIVE RESPONSE; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG RESISTANCE; DRUG RESPONSE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; METABOLISM; PHOSPHORYLATION; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; ERBB RECEPTORS; HUMANS; IMIDAZOLES; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; QUINOLINES; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84899962204     PISSN: 08986568     EISSN: 18733913     Source Type: Journal    
DOI: 10.1016/j.cellsig.2014.03.013     Document Type: Article

References (41)

1. Gioeli D., Wunderlich W., Sebolt-Leopold J., Bekiranov S., Wulfkuhle J.D., Petricoin E.F., et al. Mol. Cancer Ther. 2011.
2. Liska D., Chen C.-T., Bachleitner-Hofmann T., Christensen J.G., Weiser M.R. Clin. Cancer Res. 2011, 17:472-482.
3. Chen Xi, Zhou Jian-Ya, Zhao Jing, Chen Jun-Jun, Ma Shan-Ni, Zhou Jian-Ying Anti-Cancer Drugs 2013, 24:1039-1046.
4. Serra V., Scaltriti M., Prudkin L., Eichhorn P.J.A., Ibrahim Y.H., Chandarlapaty S., et al. Oncogene 2011, 30:2547-2557.
5. Carracedo A., Ma L., Teruya-Feldstein J., Rojo F., Salmena L., Alimonti A., et al. J. Clin. Invest. 2008, 118:3065-3074.
6. Turke A.B., Song Y., Costa C., Cook R., Arteaga C.L., Asara J.M., et al. Cancer Res. 2012, 72:3228-3237.
7. Chakrabarty A., Sánchez V., Kuba M.G., Rinehart C., Arteaga C.L. Proc. Natl. Acad. Sci. 2012, 109:2718-2723.
8. Chandarlapaty S., Sawai A., Scaltriti M., Rodrik-Outmezguine V., Grbovic-Huezo O., Serra V., et al. Cancer Cell 2011, 19:58-71.
9. Nazarian R., Shi H., Wang Q., Kong X., Koya R.C., Lee H., et al. Nature 2010, 468:973-977.
10. Myatt S.S., Lam E.W.-F. Nat. Rev. Cancer 2007, 7:847-859.
11. Basile K.J., Abel E.V., Aplin A.E. Oncogene 2012, 31:2471-2479.
12. Duncan J.S., Whittle M.C., Nakamura K., Abell A.N., Midland A.A., Zawistowski J.S., et al. Cell 2012, 149:307-321.
13. Held M.A., Langdon C.G., Platt J.T., Graham-Steed T., Liu Z., Chakraborty A., et al. Cancer Discov. 2012.
14. Axelrod M.J., Gordon V., Conaway M., Tarcsafalvi A., Neitzke D.J., Gioeli D., et al. Oncotarget April 2013, 4(4).
15. Axelrod M., Ou Z., Brett L.K., Zhang L., Lopez E.R., Tamayo A.T., et al. Leukemia 2013.
16. Roller D., Axelrod M., Capaldo B., Jensen K., Mackey A., Weber M.J., et al. Mol. Cancer Ther. 2012.
17. Eichhorn P.J.A., Gili M., Scaltriti M., Serra V., Guzman M., Nijkamp W., et al. Cancer Res. 2008, 68:9221-9230.
18. Carlson J.M., Doyle J. Phys. Rev. Lett. 2000, 84:2529-2532.
19. Kitano H. Nat. Rev. Drug Discov. 2007, 6:202-210.
20. Schalm S.S., Blenis J. Curr. Biol. 2002, 12:632-639.
21. Gordon V., Bhadel S., Wunderlich W., Zhang J., Ficarro S.B., Mollah S.A., et al. Mol. Endocrinol. 2010, 24:2267-2280.
22. Montgomery D.C. Design and Analysis of Experiments 2009, John Wiley & Sons, New York. 7th ed.
23. Bliss C. Ann. Appl. Biol. 1939, 585-615.
24. Fitzgerald J.B., Schoeberl B., Nielsen U.B., Sorger P.K. Nat. Chem. Biol. 2006, 2:458-466.
25. Grimshaw K.M., Hunter L.-J.K., Yap T.A., Heaton S.P., Walton M.I., Woodhead S.J., et al. Mol. Cancer Ther. 2010.
26. Davies S.P., Reddy H., Calvano M., Cohen P. Biochem. J. 2000, 95-105. 95-105.
27. Young N.R., Liu J., Pierce C., Wei T.-F., Grushko T., Olopade O.I., et al. Mol. Oncol. 2013, 7:359-368.
28. Mriouah Jihane, Boura Cedric, Pinel Sophie, Chretien Anne-Sophie, Fifre Alexandre, Merlin Jean-Louis, et al. Int. J. Cancer 2010, 37:1555-1563.
29. Egerod F.L., Nielsen H.S., Iversen L., Thorup I., Storgaard T., Oleksiewicz M.B. Biomarkers 2005, 10:295-309.
30. Degen M., Natarajan E., Barron P., Widlund H.R., Rheinwald J.G. Am. J. Pathol. 2012, 180:2462-2478.
31. Pinto A.P., Degen M., Barron P., Crum C.P., Rheinwald J.G. Mod. Pathol. 2013, 26:1498-1507.
32. Hennessy B.T., Lu Y., Poradosu E., Yu Q., Yu S., Hall H., et al. Clin. Cancer Res. 2007, 13:7421-7431.
33. Perl A.E., Kasner M.T., Shank D., Luger S.M., Carroll M. Clin. Cancer Res. 2012, 18:1716-1725.
34. Ruvinsky I., Sharon N., Lerer T., Cohen H., Stolovich-Rain M., Nir T., et al. Genes Dev. 2005, 19:2199-2211.
35. Simm A., Hoppe V., Karbach D., Leicht M., Fenn A., Hoppe J. Exp. Cell Res. 1998, 244:379-393.
36. Gafford G.M., Parsons R.G., Helmstetter F.J. Neuroscience 2011, 182:98-104.
37. Dagon Y., Hur E., Zheng B., Wellenstein K., Cantley L.C., Kahn B.B. Cell Metab. 2012, 16:104-112.
38. Harada H., Andersen J.S., Mann M., Terada N., Korsmeyer S.J. Proc. Natl. Acad. Sci. 2001, 98:9666-9670.
39. She Q.-B., Halilovic E., Ye Q., Zhen W., Shirasawa S., Sasazuki T., et al. Cancer Cell 2010, 18:39-51.
40. Martineau Y., Azar R., Muller D., Lasfargues C., El Khawand S., Anesia R., et al. Oncogene 2013.
41. Wang Leiping, Zhang Qunling, Zhang Jian, Sun Si, Guo Haiyi, Jia Zhen, et al. BMC Cancer 2011, 11.